Minimizing Tuberculosis Risk in Patients Receiving Anti-TNF Therapy

Hanif Esmail^{1

2}, Robert J Wilkinson^{1

3

4}

Affiliations

¹ 1 Wellcome Center for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town, South Africa.
² 2 Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
³ 3 Department of Medicine, Imperial College London, London, United Kingdom; and.
⁴ 4 The Francis Crick Institute, London, United Kingdom.

Editorial

Hanif Esmail et al. Ann Am Thorac Soc. 2017 May.

. 2017 May;14(5):621-623.

doi: 10.1513/AnnalsATS.201701-055ED.

Hanif Esmail^{1

2}, Robert J Wilkinson^{1

3

4}

¹ 1 Wellcome Center for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town, South Africa.
² 2 Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
³ 3 Department of Medicine, Imperial College London, London, United Kingdom; and.
⁴ 4 The Francis Crick Institute, London, United Kingdom.

No abstract available

Comment on

Efficacy of Treatment for Latent Tuberculosis in Patients Undergoing Treatment with a Tumor Necrosis Factor Antagonist.
Lee J, Kim E, Jang EJ, Lee CH, Lee EY, Im JP, Han SK, Yim JJ. Lee J, et al. Ann Am Thorac Soc. 2017 May;14(5):690-697. doi: 10.1513/AnnalsATS.201608-647OC. Ann Am Thorac Soc. 2017. PMID: 28253020

1. Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol. 2010;161:1–9. - PMC - PubMed
1. Horsburgh CR, Jr, Rubin EJ. Clinical practice: latent tuberculosis infection in the United States. N Engl J Med. 2011;364:1441–1448. - PubMed
1. Ledingham J, Wilkinson C, Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti–TNF-α treatments. Rheumatology (Oxford) 2005;44:1205–1206. - PubMed
1. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent. N Engl J Med. 2001;345:1098–1104. - PubMed
1. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B, Hellmich B, Groves R, Schreiber S, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010;36:1185–1206. - PubMed